$KPRX Balance Sheet | Understand Stock

$KPRX

$1.76 -$0.60 (25.42%) Close

$KPRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD; shares in millions, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current Assets:
Cash and Cash Equivalents
Short-Term Investments
Prepaid Expenses and Other Current Assets
Collaboration Receivables
Tax Receivables
Tax and Other Receivables
Prepaid Collaboration Expenses
Total Current Assets
Non-Current Assets:
Property and Equipment, Net
Restricted Cash
Goodwill
Intangible Assets and In-Process R&D, Net
Operating Lease Right-of-Use Assets
Other Assets

Total Assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts Payable
Accrued Expenses
Accrued Collaboration Credit
Operating Lease Liabilities
Contingent Consideration, Short-Term
Total Current Liabilities
Non-Current Liabilities:
Contingent Consideration
Deferred Tax Liability
Deferred Collaboration Revenue
Non-Current Operating Lease Liabilities
Total Non-Current Liabilities
Total Liabilities
Stockholders’ Equity:
Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Common Stock, $0.01 Par Value: 150,000,000 shares authorized; 4,427,167 and 3,761,739 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Total Stockholders’ Equity
Total Liabilities and Stockholders’ Equity
Common stock, shares authorized (in shares)
Common stock, shares, outstanding (in shares)

Comments